RAPT Therapeutics, a Phase 1 biotech developing therapies for cancer and inflammatory diseases, filed an amendment on Tuesday with the SEC. It had previously filed in July 2019 to raise $75 million by offering 5 million shares at a range of $14 to $16, to command a fully diluted market value of $351 million, before postponing on August 1, 2019.
In the latest filing, BofA Merrill Lynch is no longer the lead bookrunner. The company updated their financials as of June 30, 2019. It also removed the VP of Human Resources and added independent director Wendye Robbins, CEO of Blade Therapeutics. Lead inflammation drug candidate RPT193 entered the clinic in August 2019.
The South San Francisco, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol RAPT. RAPT Therapeutics filed confidentially on May 24, 2019. BMO Capital Markets, Wells Fargo Securities, and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
